Find an abstract and a link to most of the publications produced by Nordic Bioscience
The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patien...
November 18, 2016
Journal:
Alzheimers Dement
Author:
O'Bryant SE, Mielke MM, Rissman RA, Lista S, Vanderstichele H, Zetterberg H, Lewczuk P, Posner H, Hall J, Johnson L, Fong YL, Luthman J, Jeromin A, Batrla-Utermann R, Villarreal A, Britton G, Snyder PJ, Henriksen K, Grammas P, Gupta V, Martins R, Hampel H
The lack of readily available biomarkers is a significant hindrance toward progressing to effective therapeutic and preventative strategies for Alzheimer's disease (AD). Blood-based biomarkers have potential to overcome access and cost barriers and greatly facilitate advanced neuroimaging and cerebr...
May 11, 2015
Journal:
Alzheimers Dement
Author:
O'Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S, Bazenet C, Soares H, Lovestone S, Hampel H, Blennow K, Graff-Radford N, Laske C, Breteler M, Shaw L, Trojanowski JQ, Schupf N, Rissman RA, Fagan AM, Oberoi P, Umek R, Weiner MW, Grammas P, Posner H, Martins R, Carrillo MC, Montine TJ
Alzheimers disease is the public health crisis of the 21st century. There is a clear need for a widely available, inexpensive and reliable method to diagnosis Alzheimers disease in the earliest stages, track disease progression, and accelerate clinical development of new therapeutics. One avenue of ...
January 10, 2014
Journal:
Alzheimers Dement
Author:
Fillit HM, Weiner MW, Shineman DW, Bain LJ, West T, Ward M, Trushina E, Teeling J, Soares H, Sarasa M, O'Bryant SE, Mielke MM, Lovestone S, Jeromin A, Henriksen K, Grodstein F, Carrillo MC, Snyder HM, Sjögren M
Treatment of Alzheimer's disease (AD) is significantly hampered by the lack of easily accessible biomarkers that can detect disease presence and predict disease risk reliably. Fluid biomarkers of AD currently provide indications of disease stage; however, they are not robust predictors of disease pr...
January 10, 2014
Journal:
Alzheimers Dement
Author:
Henriksen K, O'Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, Blennow K, Lönneborg A, Wyss-Coray T, Soares H, Bazanet C, Sjögren M, Hu W, Lovestone S, Karsdal MA, Weiner MW, Blood-Based Biomarker Interest Group
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.